The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Azole Susceptibility Profiles of More than 9,000 Clinical Yeast Isolates Belonging to 40 Common and Rare Species
Open accessAbstract
Invasive yeast infections represent a major global public health issue, and only few antifungal agents are available. Azoles are one of the classes of antifungals used for treatment of invasive candidiasis. The determination of antifungal susceptibility profiles using standardized methods is important to identify resistant isolates and to uncover the potential emergence of intrinsically resistant species.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In multiple population studies over the last two decades, C. albicans is almost uniformly susceptible to fluconazole, the echinocandins, and amphotericin B.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [102]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resistance to fluconazole is uncommon, with rates generally ranging between 0% and 3%, but averaging less than 1% overall.27,62,102,103,109”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [102]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
The Fungal Holomorph: Mitotic, Meiotic and Pleomorphic Speciation in Fungal Systematics
Reynolds, D. R., & Taylor, J. R. (1993) · Cited by 973
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825 · cited 1×
“parapsilosis isolates similar to that reported in international surveys (17, 19, 20, 28, 44).”
Resultde Hoog, G. S., & van den Ende, A. H. G. G. (1998) · Mycoses · doi:10.1111/j.1439-0507.1998.tb00321.x · Cited by 574
Arendrup, M. C., Boekhout, T., Akova, M., Meis, J. F., Cornely, O. A., & Lortholary, O. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12360 · Cited by 529
Self-citationCandidiasis and Mechanisms of Antifungal Resistance
Bhattacharya, S., Sae-Tia, S., & Fries, B. C. (2020) · Antibiotics · doi:10.3390/antibiotics9060312 · Cited by 474 · cited 1×
“accumulation of toxic 14-a-demethylated sterols in the membrane (9).”
BackgroundPopulation-Based Analysis of Invasive Fungal Infections, France, 2001–2010
Bitar, D., Lortholary, O., Le Strat, Y., Nicolau, J., Coignard, B., Tattevin, P., Che, D., & Dromer, F. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2007.140087 · Cited by 426 · cited 1×
“(iii) Bias related to the isolates analyzed could be a factor, knowing that 22% of the isolates were sent for expert analysis following therapeutic failure and were not part of the epidemiological surveys (2, 45).”
BackgroundSelf-citationSurveillance for control of antimicrobial resistance
Tacconelli, E., Sifakis, F., Harbarth, S., Schrijver, R., van Mourik, M., Voss, A., Sharland, M., Rajendran, N. B., Rodríguez-Baño, J., Bielicki, J., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30485-1 · Cited by 376
Antifungal Susceptibility Testing: Current Approaches
Berkow, E. L., Lockhart, S. R., & Ostrosky-Zeichner, L. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00069-19 · Cited by 368 · cited 1×
“Centralized data are therefore important for these species to determine their normal susceptibility profiles (10).”
BackgroundThe French Mycosis Study Group, Lortholary, O., Renaudat, C., Sitbon, K., Madec, Y., Denoeud-Ndam, L., Wolff, M., Fontanet, A., Bretagne, S., & Dromer, F. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3408-3 · Cited by 312
Self-citationArendrup, M. C., Friberg, N., Mares, M., Kahlmeter, G., Meletiadis, J., Guinea, J., Arendrup, M. C., Meletiadis, J., Guinea, J., Friberg, N., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.06.007 · Cited by 238
Sequence Analysis of the Ribosomal DNA Intergenic Spacer 1 Regions of Trichosporon Species
Sugita, T., Nakajima, M., Ikeda, R., Matsushima, T., & Shinoda, T. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.5.1826-1830.2002 · Cited by 215
Update on Candida krusei , a potential multidrug-resistant pathogen
Jamiu, A. T., Albertyn, J., Sebolai, O. M., & Pohl, C. H. (2020) · Medical Mycology · doi:10.1093/mmy/myaa031 · Cited by 211
Lengeler, K. B., Cox, G. M., & Heitman, J. (2001) · Infection and Immunity · doi:10.1128/iai.69.1.115-122.2001 · Cited by 206 · cited 1×
“neoformans isolates by PCR amplification of part of the GPA1 and PAK1 genes using a triplex PCR with primers specific for the serotype previously described (55).”
MethodEpidemiology and Clinical Features of Invasive Fungal Infection in a US Health Care Network
Webb, B. J., Ferraro, J. P., Rea, S., Kaufusi, S., Goodman, B. E., & Spalding, J. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy187 · Cited by 188
Masclaux, F., Guého, E., de Hoog, G. S., & Christen, R. (1995) · Medical Mycology · doi:10.1080/02681219580000651 · Cited by 186 · cited 2×
“For all isolates, PCR and sequencing of internal transcribed spacer 1 (ITS1)-5.8S-ITS2 and D1D2 regions were performed, except for C. glabrata, C. tropicalis, P. kudriavzevii, and K. marxianus, for which the V9D/LS266 (48, 49) and NL1/NL4 (50) primers, respectively, were used.”
Cantón, E., Pemán, J., Quindós, G., Eraso, E., Miranda-Zapico, I., Álvarez, M., Merino, P., Campos-Herrero, M. I., Marco, F., de la Pedrosa, E. G. G., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00466-11 · Cited by 184
Donnelly, S. M., Sullivan, D. J., Shanley, D. B., & Coleman, D. C. (1999) · Microbiology · doi:10.1099/13500872-145-8-1871 · Cited by 153
Guinea, J., Zaragoza, Ó., Escribano, P., Martín‐Mazuelos, E., Pemán, J., Sánchez, F., & Cuenca‐Estrella, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02155-13 · Cited by 149
The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
Arastehfar, A., Lass-Flörl, C., Garcia-Rubio, R., Daneshnia, F., Ilkit, M., Boekhout, T., Gabaldon, T., & Perlin, D. S. (2020) · Journal of Fungi · doi:10.3390/jof6030138 · Cited by 145 · cited 1×
“Despite reports of azole resistance acquired after treatment, in common and rare yeast species, and descriptions of an increasing percentage of resistant isolates (39), this phenomenon remains rare (1, 16, 40, 41) or has geographical specificity (42, 43) and seems to concern especially C.”
BackgroundThe risk and clinical outcome of candidemia depending on underlying malignancy
The French Mycoses Study Group, Lortholary, O., Renaudat, C., Sitbon, K., Desnos‐Ollivier, M., Bretagne, S., & Dromer, F. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4743-y · Cited by 141
Self-citationCastanheira, M., Deshpande, L. M., Davis, A. P., Rhomberg, P. R., & Pfaller, M. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00906-17 · Cited by 119 · cited 1×
“Despite reports of azole resistance acquired after treatment, in common and rare yeast species, and descriptions of an increasing percentage of resistant isolates (39), this phenomenon remains rare (1, 16, 40, 41) or has geographical specificity (42, 43) and seems to concern especially C.”
BackgroundXiao, M., Chen, S. C.-A., Kong, F., Xu, X.-L., Yan, L., Kong, H.-S., Fan, X., Hou, X., Cheng, J.-W., Zhou, M.-L., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz573 · Cited by 115 · cited 6×
“(ii) Geographic specificity and/or local outbreak could be responsible, as described, for instance, in the multicentric CHIF-Net study (19) and in a national survey in Belgium (43), but none was reported to our knowledge.”
BackgroundMethodResultInfluentialXiao, M., Sun, Z., Kang, M., Guo, D., Liao, K., Chen, S. C.-A., Kong, F., Fan, X., Cheng, J., Hou, X., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00577-18 · Cited by 114
Estimating the burden of invasive and serious fungal disease in the United Kingdom
Pegorie, M., Denning, D. W., & Welfare, W. (2017) · Journal of Infection · doi:10.1016/j.jinf.2016.10.005 · Cited by 104
An estimation of burden of serious fungal infections in France
Gangneux, J., Bougnoux, M., Hennequin, C., Godet, C., Chandenier, J., Denning, D. W., & Dupont, B. (2016) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2016.11.001 · Cited by 104
Gago, S., García‐Rodas, R., Cuesta, I., Mellado, E., & Alastruey‐Izquierdo, A. (2013) · Virulence · doi:10.4161/viru.26973 · Cited by 103 · cited 1×
“metapsilosis has a reduced ability to produce some of the known virulence factors (30).”
BackgroundFungemia due to rare opportunistic yeasts: data from a population-based surveillance in Spain
Fernández‐Ruiz, M., Guinea, J., Puig‐Asensio, M., Zaragoza, Ó., Almirante, B., Cuenca‐Estrella, M., Aguado, J. M., on behalf of the CANDIPOP Project, & REIPI, G.-G. (. A. (2016) · Medical Mycology · doi:10.1093/mmy/myw055 · Cited by 95
Epidemiology and reporting of candidaemia in Belgium: a multi-centre study
Trouvé, C., Blot, S. I., Hayette, M., Jonckheere, S., Patteet, S., Rodriguez‐Villalobos, H., Symoens, F., Wijngaerden, E. V., & Lagrou, K. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2841-3 · Cited by 81 · cited 3×
“(ii) Geographic specificity and/or local outbreak could be responsible, as described, for instance, in the multicentric CHIF-Net study (19) and in a national survey in Belgium (43), but none was reported to our knowledge.”
BackgroundBorman, A. M., Muller, J., Walsh-Quantick, J., Székely, A., Patterson, Z., Palmer, M. D., Fraser, M., & Johnson, E. M. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz568 · Cited by 75
Bretagne, S., Renaudat, C., Desnos‐Ollivier, M., Sitbon, K., Lortholary, O., Dromer, F., & on behalf of the French Mycosis Study Group (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx045 · Cited by 67
Self-citationPfaller, M. A., Messer, S. A., Jones, R. N., & Castanheira, M. (2015) · The Journal of Antibiotics · doi:10.1038/ja.2015.29 · Cited by 64
Guzmán, B., Lachance, M., & Herrera, C. M. (2013) · Molecular Phylogenetics and Evolution · doi:10.1016/j.ympev.2013.04.003 · Cited by 61
Pfaller, M. A., Carvalhaes, C. G., Smith, C. J., Diekema, D. J., & Castanheira, M. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115016 · Cited by 59
Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom
Borman, A. M., Muller, J., Walsh-Quantick, J., Székely, A., Patterson, Z., Palmer, M. D., Fraser, M., & Johnson, E. M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00211-19 · Cited by 58 · cited 3×
“parapsilosis isolates similar to that reported in international surveys (17, 19, 20, 28, 44).”
BackgroundResultReporting an outbreak of Candida pelliculosa fungemia in a neonatal intensive care unit
Lin, H., Lin, S.-P., Su, B.-H., Ho, M., Ho, C., Lee, C.-Y., Lin, M.-H., Hsieh, H.-Y., Lin, H.-C., Li, T., et al. (2012) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2012.07.013 · Cited by 56
Astvad, K. M. T., Hare, R. K., & Arendrup, M. C. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.03.023 · Cited by 52 · cited 1×
“lusitaniae can be considered susceptible in vitro to fluconazole, voriconazole, and posaconazole (14, 16, 18, 19, 21), while (i) C.”
BackgroundXiao, M., Chen, S. C. ‐., Kong, F., Fan, X., Cheng, J., Hou, X., Zhou, M., Wang, H., & Xu, Y. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s173805 · Cited by 51
Pfaller, M. A., Castanheira, M., Messer, S. A., & Jones, R. N. (2015) · Mycoses · doi:10.1111/myc.12299 · Cited by 50
Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015–2017)
Desnos‐Ollivier, M., Bretagne, S., Boullié, A., Gautier, C., Dromer, F., & Lortholary, O. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.02.007 · Cited by 44
Self-citationAntifungal susceptibility profiles of rare ascomycetous yeasts
Hansen, A. P., Lass‐Flörl, C., Lackner, M., Rare Yeast Study Group, Aigner, M., Alastruey‐Izquierdo, A., Arıkan-Akdağlı, S., Bader, O., Becker, K., Boekhout, T., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz231 · Cited by 43
Desnos‐Ollivier, M., Robert, V., Raoux‐Barbot, D., Groenewald, M., & Dromer, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032278 · Cited by 42 · cited 1×
“auris, can also be considered intrinsically resistant to voriconazole and posaconazole (19, 25, 26).”
BackgroundSelf-citationBassetti, M., Vena, A., Bouza, E., Peghin, M., Muñoz, P., Righi, E., Pea, F., Lackner, M., & Lass-Flörl, C. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.02.017 · Cited by 40 · cited 1×
“2% in the SENTRY and ARTEMIS studies, depending on the continent (46), and Borman et al.”
BackgroundSequence-based identification of species belonging to the genus
Martorell, P., Fernández-Espinar, M. T., & Querol, A. (2005) · FEMS Yeast Research · doi:10.1016/j.femsyr.2005.05.002 · Cited by 36
Jung, J., Moon, Y. S., Yoo, J. A., Lim, J., Jeong, J., & Jun, J. (2017) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2017.05.005 · Cited by 35
Cyberlindnera fabianii fungaemia outbreak in preterm neonates in Kuwait and literature review
Al‐Sweih, N., Ahmad, S., Khan, S. I., Joseph, L., Asadzadeh, M., & Khan, Z. (2018) · Mycoses · doi:10.1111/myc.12846 · Cited by 34
Lodderomyces elongisporus: a bloodstream pathogen of greater clinical significance
Alobaid, K., Ahmad, S., Joseph, L., & Khan, Z. (2018) · New Microbes and New Infections · doi:10.1016/j.nmni.2018.07.004 · Cited by 33
Resolutive Candida utilis fungemia in a nonneutropenic patient
Bougnoux, M. E., Gueho, E., & Potocka, A. C. (1993) · Journal of Clinical Microbiology · doi:10.1128/jcm.31.6.1644-1645.1993 · Cited by 30
Identification and Antifungal Susceptibility Profiles of Cyberlindnera fabianii in Korea
Park, J., Oh, J., Sang, H., Shrestha, B., Lee, H., Koo, J., Cho, S., Choi, J. S., Lee, M.-H., Kim, J., et al. (2019) · Mycobiology · doi:10.1080/12298093.2019.1651592 · Cited by 27
Zhou, M., Yu, S.-Y., Kudinha, T., Xiao, M., Wang, H., Xu, Y., & Zhao, H. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s211033 · Cited by 22
Dutra, V. R., Silva, L. F., Oliveira, A. N. M., Beirigo, E. D. F., Arthur, V. M., da Silva, R. B., Ferreira, T. B., Andrade-Silva, L. E., da Silva, M. V., Fonseca, F. M., et al. (2020) · Journal of Fungi · doi:10.3390/jof6030147 · Cited by 18
Lass‐Flörl, C., Mayr, A., Aigner, M., Lackner, M., & Orth‐Höller, D. (2018) · Infection · doi:10.1007/s15010-018-1170-0 · Cited by 17
Jung, I. Y., Jeong, S. J., Kim, Y. K., Kim, H. Y., Song, Y. G., Kim, J. M., & Choi, J. Y. (2020) · Medicine · doi:10.1097/md.0000000000019494 · Cited by 15
Susceptibility of uncommon Candida species to systemic antifungals by the EUCAST methodology
Díaz-García, J., Alcalá, L., Martín‐Rabadán, P., Mesquida, A., Sánchez‐Carrillo, C., Reigadas, E., Muñóz, P., Escribano, P., & Guinea, J. (2019) · Medical Mycology · doi:10.1093/mmy/myz121 · Cited by 9
Research works printed but not linked: 1
- 10.1093/0fid/ofy187 · doi:10.1093/0fid/ofy187
Cited by
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
“27,62,102,103,109 In many parts of the world, C. glabrata is the second most common cause of IC, particularly affecting older individuals and those with significant underlying immunosuppression.”
BackgroundBretagne, S., Sitbon, K., Desnos‐Ollivier, M., Garcia‐Hermoso, D., Letscher‐Bru, V., Cassaing, S., Millon, L., Morio, F., Gangneux, J., Hasseine, L., et al. (2022) · mBio · doi:10.1128/mbio.00920-22 · Cited by 113
Self-citationBoutin, C.-A., Durocher, F., Beauchemin, S., Ziegler, D., Chakra, C. N. A., & Dufresne, S. F. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae203 · Cited by 79
“In the French study, the MICs to voriconazole and posaconazole were generally low, but posaconazole MIC distribution for S. capitata was slightly higher than voriconazole [27].”
BackgroundNon-Saccharomyces yeasts for beer production: Insights into safety aspects and considerations
Miguel, G. A., Carlsen, S., Arneborg, N., Saerens, S., Laulund, S., & Knudsen, G. M. (2022) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2022.109951 · Cited by 75
Noster, J., Koeppel, M. B., Desnos‐Ollivier, M., Aigner, M., Bader, O., Dichtl, K., Göttig, S., Haas, A., Kurzai, O., Pranada, A. B., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01834-21 · Cited by 33
“All isolates had previously been identified in the respective institutions as M. capitatus/M. clavatus, Blastoschizomyces, or Geotrichum species by different methods, including microscopy, biochemical analysis (Vitek2, API 32C [bioMérieux, Nürtingen, Germany]), or MALDI-TOF MS. February 2022 Volume 66 Issue 2 e01834-2…”
MethodSelf-citation
Metadata
- Authors
- Desnos-Ollivier, M., Lortholary, O., Bretagne, S., & Dromer, F.
- Affiliations
- Institut Pasteur, CNRS, Molecular Mycology Unit, National Reference Center for Invasive Mycoses and Antifungals, UMR2000, Paris, France
- Hôpital Necker-Enfants Malades (FR)
- Centre National de la Recherche Scientifique (FR)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2021-05-18
- Volume
- 65
- Issue
- 6
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC8315974
- OpenAlex
- W3147574361
- Cited by
- 44
- References
- 55
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 9 · 2023: 12 · 2022: 7 · 2021: 2
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- doi.org/10.1128/ASMCopyrightv2 (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc)
- Funders
- Sante Publique France
- Institut Pasteur
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- azole susceptibility, clinical yeast isolates, invasive candidiasis, antifungal resistance, Candida species, antifungal susceptibility testing
- MeSH terms
- Antifungal Agents, Azoles, Saccharomycetales, France, Microbial Sensitivity Tests, Pichia, Rhodotorula, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.